JMT108 / CSPC Pharma - LARVOL DELTA

JMT108-001: First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=400 | Recruiting | Sponsor: Shanghai JMT-Bio Inc. | Phase classification: P1 ➔ P1/2 | N=270 ➔ 400

Enrollment change • First-in-human • Phase classification • Oncology • Solid Tumor

JMT108-001: First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=270 | Recruiting | Sponsor: Shanghai JMT-Bio Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (HKEXnews) - "The board of directors (the 'Board') of CSPC Pharmaceutical Group Limited (the 'Company', together with its subsidiaries, the 'Group') is pleased to announce that JMT108 (the 'Product'), a new Class I bi-functional fusion protein drug developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S....The indication for this approval is advanced malignant tumors."

IND • Oncology

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=270 | Not yet recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P1 trial • Oncology • Solid Tumor

JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (HKEXnews) - "The board of directors (the 'Board') of CSPC Pharmaceutical Group Limited (the 'Company', together with its subsidiaries, the 'Group') is pleased to announce that JMT108 (the 'Product'), a new Class I bi-functional fusion protein drug developed by the Group, has been approved by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. The Product is a recombinant fully human anti-PD-1/IL-15 bi-functional fusion protein, which relieves immunosuppression on PD-1 positive tumor infiltrating immune cells caused by the interaction of PD-1 and PD-L1....The indication for this approval is advanced malignant tumors."

New trial • Oncology